Antimyeloma effects of the heat shock protein 70 molecular chaperone inhibitor MAL3-101

Journal of Oncology

Volumn , Issue , 2011, Pages

  Braunstein, Marc J ^a   Scott, Sadeaqua S ^a   Scott, Craig M ^b,c   Behrman, Shannon ^d   Walter, Peter ^d   Wipf, Peter ^b   Coplan, Jeremy D ^a   Chrico, William ^a   Joseph, Danielle ^a   Brodsky, Jeffrey L ^b   Batuman, Olcay ^a  

^a Downstate Health Sciences University   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c CLARION UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; HEAT SHOCK PROTEIN 70; MAL 3101; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; HUMAN; HUMAN CELL; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PLASMACYTOMA; TUMOR XENOGRAFT;

EID: 81555207195     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2011/232037     Document Type: Article

References (55)

1. Fewell S. W., Smith C. M., Lyon M. A., Dumitrescu T. P., Wipf P., Day B. W., Brodsky J. L., Small molecule modulators of endogenous and co-chaperone-stimulated Hsp70 ATPase activity Journal of Biological Chemistry 2004 279 49 51131 51140 (Pubitemid 40017855)
2. Rajkumar S. V., Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management American Journal of Hematology 2011 86 1 57 65
3. Barlogie B., Kyle R. A., Anderson K. C., Greipp P. R., Lazarus H. M., Hurd D. D., McCoy J., Dakhil S. R., Lanier K. S., Chapman R. A., Cromer J. N., Salmon S. E., Durie B., Crowley J. C., Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US intergroup trial S9321 Journal of Clinical Oncology 2006 24 6 929 936 (Pubitemid 46638847)
4. Richardson P. G., Weller E., Lonial S., Jakubowiak A. J., Jagannath S., Raje N. S., Avigan D. E., Xie W., Ghobrial I. M., Schlossman R. L., Mazumder A., Munshi N. C., Vesole D. H., Joyce R., Kaufman J. L., Doss D., Warren D. L., Lunde L. E., Kaster S., DeLaney C., Hideshima T., Mitsiades C. S., Knight R., Esseltine D. L., Anderson K. C., Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma Blood 2010 116 5 679 686
5. Bergsagel P. L., Kuehl W. M., Molecular pathogenesis and a consequent classification of multiple myeloma Journal of Clinical Oncology 2005 23 26 6333 6338 (Pubitemid 46218843)
6. Carrasco D. R., Tonon G., Huang Y., Zhang Y., Sinha R., Feng B., Stewart J. P., Zhan F., Khatry D., Protopopova M., Protopopov A., Sukhdeo K., Hanamura I., Stephens O., Barlogie B., Anderson K. C., Chin L., Shaughnessy J. D., Brennan C., DePinho R. A., High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients Cancer Cell 2006 9 4 313 325
7. Hideshima T., Mitsiades C., Tonon G., Richardson P. G., Anderson K. C., Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets Nature Reviews Cancer 2007 7 8 585 598 (Pubitemid 47106630)
8. Roccaro A. M., Hideshima T., Raje N., Kumar S., Ishitsuka K., Yasui H., Shiraishi N., Ribatti D., Nico B., Vacca A., Dammacco F., Richardson P. G., Anderson K. C., Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells Cancer Research 2006 66 1 184 191 (Pubitemid 43166024)
9. Rajkumar S. V., Mesa R. A., Fonseca R., Schroeder G., Plevak M. F., Dispenzieri A., Lacy M. Q., Lust J. A., Witzig T. E., Gertz M. A., Kyle R. A., Russell S. J., Greipp P. R., Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis Clinical Cancer Research 2002 8 7 2210 2216 (Pubitemid 34753592)
10. Vacca A., Ria R., Semeraro F., Merchionne F., Coluccia M., Boccarelli A., Scavelli C., Nico B., Gernone A., Battelli F., Tabilio A., Guidolin D., Petrucci M. T., Ribatti D., Dammacco F., Endothelial cells in the bone marrow of patients with multiple myeloma Blood 2003 102 9 3340 3348 (Pubitemid 37314776)
11. Mitsiades N., Mitsiades C. S., Poulaki V., Chauhan D., Fanourakis G., Gu X., Bailey C., Joseph M., Libermann T. A., Treon S. P., Munshi N. C., Richardson P. G., Hideshima T., Anderson K. C., Molecular sequelae of proteasome inhibition in human multiple myeloma cells Proceedings of the National Academy of Sciences of the United States of America 2002 99 22 14374 14379 (Pubitemid 35257679)
12. Lee A. H., Iwakoshi N. N., Anderson K. C., Glimcher L. H., Proteasome inhibitors disrupt the unfolded protein response in myeloma cells Proceedings of the National Academy of Sciences of the United States of America 2003 100 17 9946 9951 (Pubitemid 37087048)
13. Shah J. J., Orlowski R. Z., Proteasome inhibitors in the treatment of multiple myeloma Leukemia 2009 23 11 1964 1979
14. Catley L., Weisberg E., Kiziltepe T., Tai Y. T., Hideshima T., Neri P., Tassone P., Atadja P., Chauhan D., Munshi N. C., Anderson K. C., Aggresome induction by proteasome inhibitor bortezomib and -tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells Blood 2006 108 10 3441 3449
15. Davenport E. L., Moore H. E., Dunlop A. S., Sharp S. Y., Workman P., Morgan G. J., Davies F. E., Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells Blood 2007 110 7 2641 2649 (Pubitemid 47523188)
16. Davenport E. L., Zeisig A., Aronson L. I., Moore H. E., Hockley S., Gonzalez D., Smith E. M., Powers M. V., Sharp S. Y., Workman P., Morgan G. J., Davies F. E., Targeting heat shock protein 72 enhances Hsp90 inhibitor-induced apoptosis in myeloma Leukemia 2010 24 10 1804 1807
17. Meister S., Schubert U., Neubert K., Herrmann K., Burger R., Gramatzki M., Hahn S., Schreiber S., Wilhelm S., Herrmann M., Jck H. M., Voll R. E., Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition Cancer Research 2007 67 4 1783 1792 (Pubitemid 46383406)
18. Mitsiades C. S., Mitsiades N. S., McMullan C. J., Poulaki V., Kung A. L., Davies F. E., Morgan G., Akiyama M., Shringarpure R., Munshi N. C., Richardson P. G., Hideshima T., Chauhan D., Gu X., Bailey C., Joseph M., Libermann T. A., Rosen N. S., Anderson K. C., Antimyeloma activity of heat shock protein-90 inhibition Blood 2006 107 3 1092 1100 (Pubitemid 43156310)
19. Obeng E. A., Carlson L. M., Gutman D. M., Harrington W. J. Jr., Lee K. P., Boise L. H., Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells Blood 2006 107 12 4907 4916 (Pubitemid 43882644)
20. Richardson P. G., Mitsiades C. S., Laubach J. P., Lonial S., Chanan-Khan A. A., Anderson K. C., Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers British Journal of Haematology 2011 152 4 367 379
21. Davenport E. L., Zeisig A., Aronson L. I., Moore H. E., Hockley S., Gonzalez D., Smith E. M., Powers M. V., Sharp S. Y., Workman P., Morgan G. J., Davies F. E., Targeting heat shock protein 72 enhances Hsp90 inhibitor-induced apoptosis in myeloma Leukemia 2010 24 10 1804 1807
22. Okawa Y., Hideshima T., Steed P., Vallet S., Hall S., Huang K., Rice J., Barabasz A., Foley B., Ikeda H., Raje N., Kiziltepe T., Yasui H., Enatsu S., Anderson K. C., SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK Blood 2009 113 4 846 855
23. Rodina A., Vilenchik M., Moulick K., Aguirre J., Kim J., Chiang A., Litz J., Clement C. C., Kang Y., She Y., Wu N., Felts S., Wipf P., Massague J., Jiang X., Brodsky J. L., Krystal G. W., Chiosis G., Selective compounds define Hsp90 as a major inhibitor of apoptosis in small-cell lung cancer Nature Chemical Biology 2007 3 8 498 507 (Pubitemid 47080368)
24. Knittler M. R., Dirks S., Haas I. G., Molecular chaperones involved in protein degradation in the endoplasmic reticulum: quantitative interaction of the heat shock cognate protein BiP with partially folded immunoglobulin light chains that are degraded in the endoplasmic reticulum Proceedings of the National Academy of Sciences of the United States of America 1995 92 5 1764 1768
25. Munshi N. C., Hideshima T., Carrasco D., Shammas M., Auclair D., Davies F., Mitsiades N., Mitsiades C., Kim R. S., Li C., Rajkumar S. V., Fonseca R., Bergsagel L., Chauhan D., Anderson K. C., Identification of genes modulated in multiple myeloma using genetically identical twin samples Blood 2004 103 5 1799 1806 (Pubitemid 38268976)
26. Nimmanapalli R., Gerbino E., Dalton W. S., Gandhi V., Alsina M., HSP70 inhibition reverses cell adhesion mediated and acquired drug resistance in multiple myeloma British Journal of Haematology 2008 142 4 551 561 (Pubitemid 352020201)
27. Maloney A., Workman P., HSP90 as a new therapeutic target for cancer therapy: the story unfolds Expert Opinion on Biological Therapy 2002 2 1 3 24 (Pubitemid 34462457)
28. Brodsky J. L., Chiosis G., Hsp70 molecular chaperones: emerging roles in human disease and identification of small molecule modulators Current Topics in Medicinal Chemistry 2006 6 11 1215 1225 (Pubitemid 44110931)
29. Calderwood S. K., Heat shock proteins in breast cancer progressiona suitable case for treatment? International Journal of Hyperthermia 2010 26 7 681 685
30. Calderwood S. K., Gong J., Theriault J. R., Mambula S. S., Gray P. J. Jr., Cell stress proteins: novel immunotherapeutics Novartis Foundation Symposium 2008 291 115 131
31. Patury S., Miyata Y., Gestwicki J. E., Pharmacological targeting of the Hsp70 chaperone Current Topics in Medicinal Chemistry 2009 9 15 1337 1351
32. Rohde M., Daugaard M., Jensen M. H., Helin K., Nylandsted J., Jaattela M., Members of the heat-shock protein 70 family promote cancer cell growth by distinct mechanisms Genes and Development 2005 19 5 570 582 (Pubitemid 40314989)
33. Nylandsted J., Rohde M., Brand K., Bastholm L., Elling F., Jaattela M., Selective depletion of heat shock protein 70 (Hsp70) activates a tumor-specific death program that is independent of caspases and bypasses Bcl-2 Proceedings of the National Academy of Sciences of the United States of America 2000 97 14 7871 7876 (Pubitemid 30460740)
34. Kirkegaard T., Roth A. G., Petersen N. H., Mahalka A. K., Olsen O. D., Moilanen I., Zylicz A., Knudsen J., Sandhoff K., Arenz C., Kinnunen P. K. J., Nylandsted J., Jttel M., Hsp70 stabilizes lysosomes and reverts Niemann-Pick disease-associated lysosomal pathology Nature 2010 463 7280 549 553
35. Orlowski R. Z., Kuhn D. J., Proteasome inhibitors in cancer therapy: lessons from the first decade Clinical Cancer Research 2008 14 6 1649 1657 (Pubitemid 351469448)
36. Evans C. G., Chang L., Gestwicki J. E., Heat shock protein 70 (Hsp70) as an emerging drug target Journal of Medicinal Chemistry 2010 53 12 4585 4602
37. Polzer K., Joosten L., Gasser J., Distler J. H., Ruiz G., Baum W., Redlich K., Bobacz K., Smolen J. S., Van Den Berg W., Schett G., Zwerina J., Interleukin-1 is essential for systemic inflammatory bone loss Annals of the Rheumatic Diseases 2010 69 1 284 290
38. LeBlanc R., Catley L. P., Hideshima T., Lentzsch S., Mitsiades C. S., Mitsiades N., Neuberg D., Goloubeva O., Pien C. S., Adams J., Gupta D., Richardson P. G., Munshi N. C., Anderson K. C., Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model Cancer Research 2002 62 17 4996 5000 (Pubitemid 34984425)
39. Zhang H., Vakil V., Braunstein M., Smith E. L. P., Maroney J., Chen L., Dai K., Berenson J. R., Hussain M. M., Klueppelberg U., Norin A. J., Akman H. O., zelik T., Batuman O. A., Circulating endothelial progenitor cells in multiple myeloma: implications and significance Blood 2005 105 8 3286 3294
40. Braunstein M., Ozcelik T., Bagislar S., Vakil V., Smith E. L., Dai K., Akyerli C. B., Batuman O. A., Endothelial progenitor cells display clonal restriction in multiple myeloma BMC Cancer 2006 6, article 161
41. Anderson G., Gries M., Kurihara N., Honjo T., Anderson J., Donnenberg V., Donnenberg A., Ghobrial I., Mapara M. Y., Stirling D., Roodman D., Lentzsch S., Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1 Blood 2006 107 8 3098 3105
42. Schroder M., Kaufman R. J., The mammalian unfolded protein response Annual Review of Biochemistry 2005 74 739 789 (Pubitemid 40995523)
43. Bianchi G., Oliva L., Cascio P., Pengo N., Fontana F., Cerruti F., Orsi A., Pasqualetto E., Mezghrani A., Calbi V., Palladini G., Giuliani N., Anderson K. C., Sitia R., Cenci S., The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition Blood 2009 113 13 3040 3049
44. Hideshima T., Richardson P., Chauhan D., Palombella V. J., Elliott P. J., Adams J., Anderson K. C., The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells Cancer Research 2001 61 7 3071 3076 (Pubitemid 32691956)
45. Bernales S., McDonald K. L., Walter P., Autophagy counterbalances endoplasmic reticulum expansion during the unfolded protein response PLoS Biology 2006 4 12
46. Nakamura M., Gotoh T., Okuno Y., Tatetsu H., Sonoki T., Uneda S., Mori M., Mitsuya H., Hata H., Activation of the endoplasmic reticulum stress pathway is associated with survival of myeloma cells Leukemia and Lymphoma 2006 47 3 531 539 (Pubitemid 43102103)
47. Cenci S., Mezghrani A., Cascio P., Bianchi G., Cerruti F., Fra A., Lelouard H., Masciarelli S., Mattioli L., Oliva L., Orsi A., Pasqualetto E., Pierre P., Ruffato E., Tagliavacca L., Sitia R., Progressively impaired proteasomal capacity during terminal plasma cell differentiation EMBO Journal 2006 25 5 1104 1113 (Pubitemid 43372123)
48. Vembar S. S., Brodsky J. L., One step at a time: endoplasmic reticulum-associated degradation Nature Reviews Molecular Cell Biology 2008 9 12 944 957
49. Buchberger A., Bukau B., Sommer T., Protein quality control in the cytosol and the endoplasmic reticulum: brothers in arms Molecular Cell 2010 40 2 238 252
50. Gazdar A. F., Oie H. K., Kirsch I. R., Hollis G. F., Establishment and characterization of a human plasma cell myeloma culture having a rearranged cellular myc proto-oncogene Blood 1986 67 6 1542 1549 (Pubitemid 16075955)
51. Jolly C., Morimoto R. I., Role of the heat shock response and molecular chaperones in oncogenesis and cell death Journal of the National Cancer Institute 2000 92 19 1564 1572
52. Rigolin G. M., Fraulini C., Ciccone M., Mauro E., Bugli A. M., De Angeli C., Negrini M., Cuneo A., Castoldi G., Neoplastic circulating endothelial cells in multiple myeloma with 13q14 deletion Blood 2006 107 6 2531 2535 (Pubitemid 43345578)
53. Tanabe K., Tokumoto T., Ishikawa N., Shimizu T., Okuda H., Ito S., Shimmura H., Inui M., Harano M., Ohtsubo S., Manu M., Shiroyanagi Y., Yagisawa T., Fuchinoue S., Toma H., Effect of Deoxyspergualin on the long-term outcome of renal transplantation Transplantation Proceedings 2000 32 7 1745 1746
54. Nadeau K., Nadler S. G., Saulnier M., Tepper M. A., Walsh C. T., Quantitation of the interaction of the immunosuppressant deoxyspergualin and analogs with hsc70 and hsp90 Biochemistry 1994 33 9 2561 2567 (Pubitemid 24099664)
55. Wisen S., Bertelsen E. B., Thompson A. D., Patury S., Ung P., Chang L., Evans C. G., Walter G. M., Wipf P., Carlson H. A., Brodsky J. L., Zuiderweg E. R. P., Gestwicki J. E., Binding of a small molecule at a protein-protein interface regulates the chaperone activity of Hsp70-Hsp40 ACS Chemical Biology 2010 5 6 611 622